In this video, health-care analyst David Williamson discusses two cutting-edge but very different hepatitis C drug candidates under FDA review. A little less than a month ago, Johnson & Johnson received priority status for its simeprevir, shortening its decision time by four months.
Investors recently learned that Gilead also received priority status for its entry sofosbuvir. Watch and find out why Gilead is set to change the entire treatment paradigm for this disease and why approval for Gilead may be a boost for J&J.
Is bigger really better?
Because the company is involved in everything from baby powder to biotech, Johnson & Johnson's critics are convinced that it is spread way too thin. If you want to know if J&J is nothing but a bloated corporate whale -- or a well-diversified giant that's perfect for your portfolio -- check out the Fool's new premium report outlining the Johnson & Johnson story in terms that any investor can understand. Claim your copy by clicking here now.